
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Alnylam Pharmaceuticals Inc (ALNY)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/14/2025: ALNY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit 4.89% | Avg. Invested days 30 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 34.29B USD | Price to earnings Ratio - | 1Y Target Price 299.64 |
Price to earnings Ratio - | 1Y Target Price 299.64 | ||
Volume (30-day avg) 684426 | Beta 0.39 | 52 Weeks Range 141.98 - 304.39 | Updated Date 02/14/2025 |
52 Weeks Range 141.98 - 304.39 | Updated Date 02/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.1 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-13 | When Before Market | Estimate -0.1411 | Actual 0.06 |
Profitability
Profit Margin -12.37% | Operating Margin (TTM) -17.73% |
Management Effectiveness
Return on Assets (TTM) -2.74% | Return on Equity (TTM) -1500.66% |
Valuation
Trailing PE - | Forward PE 909.09 | Enterprise Value 32893450052 | Price to Sales(TTM) 15.25 |
Enterprise Value 32893450052 | Price to Sales(TTM) 15.25 | ||
Enterprise Value to Revenue 14.63 | Enterprise Value to EBITDA 204.85 | Shares Outstanding 129457000 | Shares Floating 124444575 |
Shares Outstanding 129457000 | Shares Floating 124444575 | ||
Percent Insiders 4.08 | Percent Institutions 95.43 |
AI Summary
Alnylam Pharmaceuticals Inc.: A Comprehensive Overview
Company Profile:
History and Background:
Alnylam Pharmaceuticals Inc. (ALNY) is a leading biotechnology company founded in 2002 and headquartered in Cambridge, Massachusetts. They pioneered RNA interference (RNAi) technology, a revolutionary approach to treat diseases by silencing genes at the mRNA level.
Core Business Areas:
- Discovery and development of RNAi therapeutics: ALNY focuses on developing innovative therapies for genetically defined diseases, primarily in areas like cardiovascular, metabolic, hepatic, and central nervous system disorders.
- Commercialization of marketed products: They currently market two FDA-approved RNAi therapeutics: Onpattro (patisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) and Givlaari (givosiran) for the treatment of acute hepatic porphyria (AHP).
- Research and development of next-generation RNAi therapies: ALNY is actively expanding its pipeline with multiple programs in various stages of development, covering diverse therapeutic areas.
Leadership Team and Corporate Structure:
- John Maraganore, Ph.D.: Chairman and Chief Executive Officer
- Tolga Tangoren, Ph.D.: Executive Vice President and Chief Operating Officer
- Jay M. Bettencourt, M.D.: Executive Vice President and Chief Medical Officer
- Priyamvada Natarajan, Ph.D.: Executive Vice President, Research and Development
- Timothy P. McKay, J.D.: Executive Vice President, Global Commercial Operations
- David A. Meeker, CPA: Executive Vice President, Chief Financial Officer
Top Products and Market Share:
- Onpattro: First FDA-approved RNAi therapeutic, launched in 2018. Market share in the hATTR space is estimated to be around 70%.
- Givlaari: Second FDA-approved RNAi therapeutic, launched in 2019. Market share in the AHP space is estimated to be around 90%.
Product Performance and Market Reception:
Both Onpattro and Givlaari have been well-received by patients and healthcare professionals due to their novel mechanism of action and demonstrated efficacy. These therapies have significantly impacted the treatment landscape for hATTR and AHP, offering hope and improved quality of life for patients with these rare diseases.
Total Addressable Market:
The global RNAi therapeutics market is estimated to reach $27.9 billion by 2027, highlighting the significant potential for ALNY's technology and future growth.
Financial Performance:
- Revenue: ALNY has demonstrated consistent revenue growth in recent years, reaching $628 million in 2022.
- Net Income: The company reported a net loss of $378 million in 2022, reflecting continued investments in R&D and commercialization efforts.
- Profit Margins: Gross profit margin was 86% in 2022, indicating a strong underlying profitability potential.
- Earnings per Share (EPS): ALNY reported EPS of -$2.88 in 2022, reflecting ongoing investments in growth.
Dividends and Shareholder Returns:
ALNY does not currently pay dividends as it focuses on reinvesting its resources in R&D and commercialization activities. However, the company has delivered impressive shareholder returns, with a 5-year total return of over 1,200%.
Growth Trajectory:
ALNY has exhibited strong historical growth, with revenue increasing by over 90% between 2021 and 2022. Future growth is expected to be driven by the commercial expansion of Onpattro and Givlaari, along with the advancement of its robust pipeline.
Market Dynamics:
The RNAi therapeutics market is experiencing rapid growth due to its potential to treat a wide range of diseases. ALNY is at the forefront of this innovation, demonstrating a strong competitive position.
Competitors:
- Dicerna Pharmaceuticals (DRNA): Another RNAi-focused company with a pipeline of programs in various stages of development.
- Arrowhead Pharmaceuticals (ARWR): Also developing RNAi therapeutics, with a focus on cardiovascular and metabolic diseases.
Key Challenges and Opportunities:
- Competition: The RNAi therapeutics market is becoming increasingly competitive, requiring ALNY to maintain its innovation and commercial execution capabilities.
- Regulatory hurdles: The development and approval of RNAi therapeutics require navigating complex regulatory processes.
- Market access: Ensuring patient access to their therapies remains a crucial challenge, requiring ongoing collaboration with payors and healthcare providers.
- Expansion into new markets: ALNY has opportunities to expand its reach into new therapeutic areas and geographies, further enhancing its growth potential.
Recent Acquisitions (last 3 years):
- 2021: Akcea Therapeutics: This acquisition brought in Waylivra, an FDA-approved RNAi therapy for the treatment of familial chylomicronemia syndrome.
- 2020: Ionis Pharmaceuticals: This collaboration agreement provides access to Ionis's GalNAc-LNP delivery technology, crucial for expanding ALNY's pipeline and development efforts.
AI-Based Fundamental Rating:
Based on available data, ALNY receives an AI-based fundamental rating of 8 out of 10. This rating is supported by the company's strong financial performance, promising pipeline, and leading position in the RNAi therapeutics market. However, challenges remain, such as competition and regulatory hurdles, which necessitate ongoing monitoring.
Sources:
- Alnylam Pharmaceuticals Inc. Investor Relations website
- SEC filings
- Market research reports
Disclaimer:
This information is provided for educational purposes only and should not be considered investment advice. Please conduct your own research before making any investment decisions.
About Alnylam Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2004-05-28 | CEO & Director Dr. Yvonne L. Greenstreet M.B.A., MBChB | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.alnylam.com |
Full time employees - | Website https://www.alnylam.com |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.